Electronics For Imaging (EFII) Numbers Impacted; Hancock Jaffe (HJLI) In Focus; Dover (DOV), Canopy Growth (CGC) Upcoming Key Date
Shares of Electronics For Imaging, Inc. (Nasdaq:EFII) plunged more than 15% in the extended session Tuesday after the company provided a below-consensus outlook and indicated that its results were impacted by weakening economic conditions experienced across its direct businesses, with customers delaying spend on capital equipment and software, which materially reduced its close rates at quarter end.
For the fourth quarter 2018, the global technology company expects revenues to be between $255M and $257M, and non-GAAP earnings per share to be in the range of $0.45-$0.47, compared to the S&P Capital IQ Consensus Estimate of $0.60 EPS on revenues of $280.32M for the period.
Electronics For Imaging provides industrial format display graphics, corrugated packaging and display, textile, and ceramic tile decoration digital inkjet printers worldwide.
**
Dr. Marc H. Glickman, Hancock Jaffe Laboratories, Inc.'s (Nasdaq:HJLI) Chief Medical Officer, will be presenting at the 6th Israeli Vascular Access Conference in Herzlia, Israel on January 16, 2019. The conference is sponsored by The Israeli Society for Vascular and Endovascular Surgery, The Israeli Society of Nephrology and Hypertension, and the Israeli Society for Interventional Radiology, and will be attended by more than 250 vascular surgeons.
HJLI is scheduled to begin a study for its CoreoGraft, bioprosthetic graft on January 29 at the Texas Heart Institute. The 30 day study will involve a series of CoreoGraft implantations tested for short term patency and flow rates, a problem which impacts a significant percentage of the 180,000 patients that have coronary bypass surgery each year in the U.S. The Company expects to have results from the CoreoGraft study available by the end of March 2019.
HJLI is also preparing for its VenoValve first-in-human trial in Bogota, Columbia, which will also begin in Q1 of 2019. The Company has begun to screen patients for the trial, and will announce the date for the first VenoValve implantations once initial patient enrollment is completed. The VenoValve was developed to treat severe cases of chronic venous insufficiency (CVI), a debilitating condition often associated with open venous ulcers and intense pain, and which afflicts approximately 4.5 million people in the U.S. and tens of millions of additional patients worldwide. There are currently no FDA approved treatments for deep venous CVI.
HJLI specializes in developing and manufacturing bioprosthetic medical devices to establish improved standards of care for treating cardiac and vascular diseases.
**
Dover Corp. (NYSE:DOV) expects to release its fourth quarter 2018 financial results before the market open on Tuesday, January 29.
Dover is a diversified global manufacturer with annual revenues of approximately $7 billion. The company delivers innovative equipment and components, specialty systems, consumable supplies, software and digital solutions, and support services through three operating segments: Engineered Systems, Fluids, and Refrigeration & Food Equipment.
**
Canopy Growth Corp. (NYSE:CGC) (TSX:WEED) will release its third quarter fiscal 2019 financial results after the closing bell on Thursday, February 14.
Canopy Growth is a world-leading diversified cannabis and hemp company, offering distinct brands and curated cannabis varieties in dried, oil and Softgel capsule forms.
****
Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. CRWEWorld Finance is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at www.crweworld.com/finance_disclaimer